TY  - JOUR
AU  - Taieb, Julien
AU  - Modest, Dominik P
AU  - Fakih, Marwan
AU  - Ciardiello, Fortunato
AU  - Van Cutsem, Eric
AU  - Elez, Elena
AU  - Gravalos, Cristina
AU  - Bragagnoli, Arinilda Campos
AU  - Barboux, Valentine
AU  - Roby, Lucas
AU  - Amellal, Nadia
AU  - Prager, Gerald W
TI  - Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
JO  - European journal of cancer
VL  - 227
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01520
SP  - 115644
PY  - 2025
AB  - This post hoc analysis of the SUNLIGHT trial sought to assess the response to treatment with trifluridine/tipiracil (FTD/TPI) + bevacizumab and FTD/TPI in patients with refractory metastatic colorectal cancer using tumor shrinkage (TS), early TS (ETS), duration of TS (DTS) and depth of response (DpR) as response-related parameters.TS was defined as any decrease from baseline of the sum of the longest diameter of target lesions. TS at first assessment was specified as ETS. DpR was defined as the maximum percentage change from baseline of the sum of the longest diameters of target lesions. DTS was defined as the time from first TS to first increase in tumor size, progressive disease, or death.In the FTD/TPI + bevacizumab group, 48 
KW  - Bevacizumab (Other)
KW  - Colorectal cancer (Other)
KW  - Depth of response (Other)
KW  - Response parameters (Other)
KW  - Trifluridine/tipiracil (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40694985
DO  - DOI:10.1016/j.ejca.2025.115644
UR  - https://inrepo02.dkfz.de/record/303095
ER  -